Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenome


  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 09 February 2013 - 11:16 PM

A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon.

Treatment with MQX-503 caused a significant improvement in skin blood flow compared with placebo. PubMed. Ann rheumatologist Dis. 2012 Dec 25. (Also see: Raynaud's Research)

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)